DocGo (NASDAQ:DCGO), which combined with Motion in November 2021, announced that it will redeem all of its outstanding warrants at 5 pm ET September 16 at a redemption price of $0.10 per warrant.
Holders may also swap their warrants on a cashless basis for 0.2233 of a common share as a part of the exchange. The company is allowed to launch this call because the last share price of its shares was $10 or above on August 12.
In fact, the company has been on a tear, rising +31.3% over the past month. It closed yesterday at $10.20 on the backs of three successive profitable quarters as a public company. DocGo most recently beat its second quarter revenue estimates by about 10% and upped its revenue guidance for the year.
Holders may also exercise their warrants at $11.50 per share until September 16.
DocGo provides “last-mile” medical services such as medical transportation and telehealth, and it has been active in providing mobile COVID-19 stations throughout the country. This morning, it also announced that it has been contracted to provide mobile health services to Medicare-eligible patients covered by New Jersey’s largest health insurer, Horizon.
Terms Tracker for the Week Ending March 14, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Once again, market volatility was the headline news this week, and while that doesn’t directly affect SPACs, it has some effect. For investors, it’s usually...
At the SPAC of Dawn The first wave of proposed SEC rules changes under the Trump administration touch upon SPACs in some unexpected ways and could portend at least a few years of peace between sponsors and their chief regulator. Earlier this month, the SEC announced that its Division of Corporation Finance would expand the...
At the SPAC of Dawn Following Wednesday’s positive CPI readings, the market is set to ingest both new jobless claims and Core PPI inflation numbers at 8:30 am ET. It might take a particularly rosy result to offset the many factors of market volatility recent. One new one got added to the bingo card this...
One of the eternal questions surrounding SPACs has been their ability or inability to match the opportunity and the performance of the traditional IPO route, and it has become received wisdom on Wall Street that SPACs don’t match up. This is ostensibly born out in in the aggregate statistics that are frequently cited. But, downside...
At the SPAC of Dawn Despite the specter of recession looming, many of the hot technology sectors that SPACs favored during the boom times appear to be coming back on the menu. Ares II (NYSE:AACT) is reportedly angling to lock down a deal with an autonomous trucking firm. Northern Genesis II and Reinvent Y each...